-
Genasense, a melanoma drug, was rejected by a panel in 2004 after its maker, Genta, argued that although the drug failed to improve survival, it shrank tumors.
FORBES: Magazine Article
-
During the commodity boom in 2001-2008, it shrank by an average of 1% a year, whereas the world's other top 20 mining-export countries grew by an average of 5% a year.
ECONOMIST: Nationalisation in South Africa
-
Genasense, a melanoma drug, was rejected by a panel in 2004 after its maker, Genta (nasdaq: GNTA - news - people ), argued that although the drug failed to improve survival, it shrank tumors.
FORBES: Dendreon Decision Could Mean FDA Shift